Illumina announced an agreement to acquire its 2016 spinoff Grail, which makes a platform for early cancer detection, but analysts balked at the $8 billion price tag and Illumina stock fell.

The post Illumina Announces $8 Billion Acquisition Of Former Cancer-Testing Spinoff Grail appeared first on Investor's Business Daily.